Mitchell Mcleod Pugh & Williams Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 123.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,156 shares of the medical research company’s stock after buying an additional 2,848 shares during the period. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Amgen were worth $888,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in AMGN. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Conservest Capital Advisors Inc. increased its position in Amgen by 0.4% in the second quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock valued at $539,000 after buying an additional 13 shares in the last quarter. Arvest Bank Trust Division increased its position in Amgen by 0.9% in the second quarter. Arvest Bank Trust Division now owns 1,508 shares of the medical research company’s stock valued at $260,000 after buying an additional 13 shares in the last quarter. First Command Financial Services Inc. increased its position in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares in the last quarter. Finally, M Holdings Securities Inc. increased its position in Amgen by 0.6% in the first quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock valued at $463,000 after buying an additional 18 shares in the last quarter. 79.53% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 0.12% during trading on Friday, reaching $169.31. 725,750 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $174.60 and a 200-day moving average of $167.37. The stock has a market capitalization of $123.54 billion, a PE ratio of 15.42 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 earnings per share. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.72%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.
TRADEMARK VIOLATION WARNING: “Amgen Inc. (AMGN) Position Increased by Mitchell Mcleod Pugh & Williams Inc.” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/08/11/amgen-inc-amgn-position-increased-by-mitchell-mcleod-pugh-williams-inc.html.
Several research analysts recently commented on AMGN shares. Deutsche Bank AG started coverage on shares of Amgen in a research note on Friday, June 23rd. They issued a “hold” rating and a $172.00 price target on the stock. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Monday, June 5th. William Blair reaffirmed a “market perform” rating on shares of Amgen in a research note on Monday, June 26th. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $165.00 price target on shares of Amgen in a research note on Friday, April 28th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.